Multisource Surveillance Study of Pregnancy and Infant Outcomes in Ocrelizumab-Exposed Women With Multiple Sclerosis (MELODIC Study)

28/02/2020
02/07/2024
EU PAS number:
EUPAS33879
Study
Planned
Subscribe
Download as PDF
Study summary
No information provided.
Study identification

EU PAS number

EUPAS33879

Study ID

40211

Official title and acronym

Multisource Surveillance Study of Pregnancy and Infant Outcomes in Ocrelizumab-Exposed Women With Multiple Sclerosis (MELODIC Study)

DARWIN EU® study

No

Study countries

Denmark
United States

Study description

This will be an observational cohort study of ocrelizumab-exposed pregnancies and two matched comparator cohorts through secondary use of data from multiple sources. The study will be conducted in existing population-based health care databases and registries. The proposed data sources include data from the US and Denmark.

Study status

Planned
Research institutions and networks

Institutions

RTI Health Solutions (RTI-HS)
France
Spain
Sweden
United Kingdom
United Kingdom (Northern Ireland)
United States
First published:
13/03/2025
Institution Not-for-profit ENCePP partner
HealthCore
First published:
01/02/2024
Institution
Optum
Germany
First published:
07/02/2014
Institution Outdated Other ENCePP partner
HealthCore Integrated Research DatabaseSM (HIRD) United States

Contact details

Andrea Margulis

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Roche
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)